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Recovery from ischemic tissue injury can be promoted 
by cell proliferation and neovascularization. Transient 
expression of four pluripotency factors (Pou5f1, Sox2, 
Myc, and Klf4) has been used to convert cell types 
but never been tested as a means to promote func-
tional recovery from ischemic injury. Here we aimed to 
determine whether transient in situ pluripotency fac-
tor expression can improve neurobehavioral function. 
Cerebral ischemia was induced by transient bilateral 
common carotid artery occlusion, after which the four 
pluripotency factors were expressed through either 
doxycycline administration into the lateral ventricle in 
transgenic mice in which the four factors are expressed 
in a doxycycline-inducible manner. Histologic evalua-
tion showed that this transient expression induced the 
proliferative generation of astrocytes and/or neural pro-
genitors, but not neurons or glial scar, and increased 
neovascularization with upregulation of angiogenic fac-
tors. Furthermore, in vivo pluripotency factor expression 
caused neuroprotective effects such as increased num-
bers of mature neurons and levels of synaptic markers 
in the striatum. Dysplasia or tumor development was 
not observed. Importantly, neurobehavioral evaluations 
such as rotarod and ladder walking tests showed that 
the expression of the four factors dramatically promoted 
functional restoration from ischemic injury. These results 
provide a basis for novel therapeutic modality develop-
ment for cerebral ischemia.
Received 25 February 2016; accepted 11 June 2016; advance online  
publication 26 July 2016. doi:10.1038/mt.2016.124
INTRODUCTION
Restoration or regeneration of damaged tissue is important 
for functional recovery from injuries or diseases. Compared 
to other mammalian organs and tissues, the brain lacks signifi-
cant regenerative capacity: An injury in brain tissue often leads 
to semipermanent functional impairment. Because proliferative 
generation of the brain cells required for functional recovery is not 
sufficiently provided by endogenous cell sources, supplementation 
with other cell types may aid recovery. Transplantation of exoge-
nous cells such as bone marrow mononuclear cells,1 bone marrow 
stromal cells,2 and neural stem cells3 has been reported to enhance 
brain tissue regeneration, leading to functional improvement. 
However, the engraftment of transplanted cells is often limited4 
and the generation of neural-lineage cells from transplanted cells 
may not be sufficient for functional restoration.5 Furthermore, cell 
transplantation into the brain can have adverse effects: Allogenic 
or xenogenic cells can be rejected by the immune system or tumor 
development can occur after cell injections.6
Previous studies reported enhancement of functional recov-
ery by augmented proliferative generation, activation, and 
mobilization of brain cells from endogenous cell sources using 
exogenously delivered humoral factors such as epidermal growth 
factor and brain-derived neurotrophic factor. Intraventricular 
delivery of brain-derived neurotrophic factor, noggin, or epider-
mal growth factor into the lateral ventricle via an adenoviral vec-
tor or an osmotic pump has been reported to activate endogenous 
neural stem/progenitor cells in the subventricular zone, leading 
to striatal regeneration and consequent functional improvement 
in mouse models of chronic hypoxic-ischemic brain injury7 
and Huntington’s disease.8,9 However, the endogenous cell types 
directly affected by these humoral factors are restricted to those 
with receptors for these factors, which might limit more robust 
functional recovery.
Yamanaka’s group showed that exogenous expression of 
four pluripotency-associated transcription factors, i.e., Pou5f1 
(octamer-binding protein, Oct4), Sox2 (SRY-box containing 
gene 2), Myc (c-myelocytomatosis oncogene, c-myc), and Klf4 
(Kruppel-like factor 4), can convert fibroblasts into pluripotent 
stem cells.10 Subsequent studies have shown that these pluripo-
tency factors can also be used to convert one cell type to another 
directly: Transient expression of pluripotency factors renders cells 













Official journal of the American Society of Gene & Cell Therapy
Correspondence: Sung-Rae Cho, Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Rehabilitation 
Hospital 5th Floor, 50 Yonsei-ro, Seodaemoon-gu, Seoul 03722, Korea. Phone: +82-2-2228-3715; E-mail: srcho918@yuhs.ac  or Hyongbum Kim, 
Department of Pharmacology, Yonsei University College of Medicine, ABMRC Room 504, 50 Yonsei-ro, Seodaemoon-gu, Seoul 03722, Korea.  
E-mail: hkim1@yuhs.ac
In Situ Pluripotency Factor Expression Promotes 
Functional Recovery From Cerebral Ischemia
Jung Hwa Seo1,2,3, Min-Young Lee1, Ji Hea Yu1,2, Myung-Sun Kim1, Myungjae Song4,5,  
Cheong Hoon Seo3, Hyongbum (Henry) Kim2,4,6 and Sung-Rae Cho1,2,7,8
1Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Korea; 2Brain Korea 21 PLUS Project for 
Medical Science, Yonsei University, Seoul, Korea; 3Department of Rehabilitation Medicine, Hallym University Burn Institute, Burn Center, Hangang 
 Sacred Heart Hospital, Seoul, Korea; 4Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea; 5 Graduate School of  Biomedical 
Science and Engineering/College of Medicine, Hanyang University, Seoul, Korea; 6Severance Biomedical Science Institute, Yonsei University College 
of Medicine, Seoul, Korea; 7Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Korea; 8Yonsei Stem Cell 
Research Center, Avison Biomedical Research Center, Seoul, Korea
MTOpen
1538 www.moleculartherapy.org vol. 24 no. 9, 1538–1549 sep. 2016
Official journal of the American Society of Gene & Cell Therapy
Pluripotency Factors Promote Recovery From Injury
type conversion into other lineages, such as neural progenitors,11 
angioblasts,12 hepatocytes,13 or cardiomyocytes,11 depending on 
the culture environment. Recently, it has been shown that these 
pluripotency factor–induced lineage conversions are achieved via 
transient acquisition of pluripotent status.14
Direct conversion of cell types without mediation of pluripo-
tent status has also been studied for possible practical applications. 
For example, fibroblasts were converted into neurons15 and neural 
progenitor cells16 by in vitro expression of defined transcription 
factors. Important potential uses of cell type conversion include 
disease modeling and regeneration of damaged tissue.17 In vitro 
central nervous system disease models using direct conversion 
have been shown to recapitulate the disease in question.18,19 In vivo 
direct conversion has also been studied as a therapeutic modal-
ity for functional recovery from damage or injury in brain tissue: 
Glial cells and transplanted fibroblasts were converted into neuro-
nal lineage cells in vivo.20–22 However, neurobehavioral functional 
improvement has never been reported using these in vivo direct 
conversion strategies.
One of the earliest noticeable responses of cells that are 
exposed to forced expression of the four pluripotency factors is 
enhanced cell proliferation, which can be observed as early as 
24 hours after induction of this expression.23 This enhanced pro-
liferation is associated molecularly with the induction of pro-
liferative genes.24 Based on this observation, we postulated that 
in situ transient expression of pluripotency factors would facilitate 
in vivo cell proliferation, a critical and essential process for recov-
ery of injured tissue. Furthermore, Myc induces neovasculariza-
tion,25 an essential process for recovery from ischemic injury.
In this study, we, for the first time, investigated whether in situ 
transient expression of pluripotency factors can enhance func-
tional recovery from ischemic injury. To address this issue, we 
used a mouse model of cerebral ischemia, in which spontaneous 
regeneration or recovery is limited. Here we show that in situ tran-
sient expression of pluripotency factors after an ischemic injury 
facilitates functional recovery, which is associated with prolifera-
tive generation of astrocytes and/or neural progenitors coupled 
with enhanced neovascularization in brain tissue.
RESULTS
In situ pluripotency factor expression increases 
new neural progenitors and astrocytes in the 
subventricular zone
To elicit in situ expression of pluripotency factors in vivo, we first 
used transgenic mice (hereafter, referred to as reprogrammable 
mice) in which the four factors, i.e., Pou5f1 (Oct4), Sox2, Myc, and 
Klf4, are expressed in a doxycycline-inducible manner.26 We vali-
dated doxycycline’s effects using embryonic fibroblasts isolated 
from reprogrammable mice. Reverse transcription polymerase 
chain reaction (RT-PCR) showed that the four pluripotency fac-
tors were expressed in the presence of 10~1,000 ng/ml doxycycline 
(Supplementary Figure S1a). To express the factors in damaged 
brain tissues in situ, we used an osmotic pump to infuse low 
(12 ng/day, DOX-L group) or high (1,200 ng/day, DOX-H group) 
amounts of doxycycline or control buffer (phosphate buffered 
saline (PBS)) into the lateral ventricle for 7 days starting immedi-
ately after 20-minute bilateral common carotid artery occlusion27 
in the reprogrammable mice (Figure 1a,b). To determine whether 
doxycycline induced expression of pluripotency factors in vivo, we 
measured expression of Sox2 using quantitative real-time poly-
merase chain reaction (qRT-PCR) 3 days after the infusion of 
doxycycline. We found that Sox2 expression in the striatum sig-
nificantly increased in mice treated with DOX-H compared with 
the other groups in a dose-dependent manner (Supplementary 
Figure S1b; P < 0.05). Although in vivo doxycycline-induced 
expression of pluripotency factors has been reported to cause 
dysplasia or tumor formation in epithelial tissues,28,29 we did not 
observe either of these effects 4 weeks after the initiation of this 
1-week low-dose doxycycline infusion (Figure 1c–e).
To determine whether this in situ expression enhances cell 
proliferation in the damaged tissue, we first determined neuro-
genesis and gliogenesis levels in the subventricular zone, the site 
of the highest expected concentration of doxycycline after diffu-
sion from the lateral ventricle. This is also the site where neural 
stem/progenitor cells, which contribute to regeneration, exist 
in the adult mammalian brain.30,31 To label proliferating cells, 
5-bromo-2-deoxyuridine (BrdU) was given to the mice every 
day for 12 days after the stereotaxic surgery. The numbers of 
BrdU+ cells in the subventricular zone in mice in the DOX-H and 
DOX-L groups were 7.7- and 4.5-fold, respectively, significantly 
higher than in the PBS control (Supplementary Table S1; Figure 
2a; P < 0.001 and P < 0.01, respectively) and the number of BrdU+ 
cells in the DOX-H group was 1.7-fold significantly higher than in 
the DOX-L group (Figure 2a; P < 0.01), indicating that pluripo-
tency factors enhance cell proliferation in the subventricular zone 
in a dose-dependent manner.
We next attempted to identify the proliferating cells by dou-
ble-staining with BrdU and cell type–specific markers such as 
βIII-tubulin (Tuj1, neuronal marker), GFAP (astrocyte marker), 
or Nestin (neural progenitor cell marker) in the subventricu-
lar zone. The numbers of BrdU+Nestin+ cells in the DOX-H and 
DOX-L groups were 26.5- and 20.4-fold, respectively, significantly 
higher than in the PBS control group (Figure 2be–g; P < 0.01 and 
P < 0.05, respectively), indicating that in situ expression of plu-
ripotency factors enhances the proliferative generation of neural 
progenitor cells. The numbers of BrdU+GFAP+ cells in the DOX-H 
and DOX-L groups were 15.2- and 10.8-fold, respectively, sig-
nificantly higher than in the PBS control group (Figure 2c,h–j; 
P < 0.001 and P < 0.01, respectively), suggesting that pluripo-
tency factor expression causes a robust proliferative generation 
of astrocytes. However, the numbers of BrdU+βIII-tubulin+ cells 
were similar among all groups (Figure 2d,k–m), suggesting that 
neurogenesis in the subventricular zone is not affected by the plu-
ripotency factors.
Pluripotency factor expression increases newly 
generated astrocytes but not neurons or glial scar in 
the striatum
Motor performances evaluated by rotarod and forelimb slip tests 
are largely affected by the striatal function. Moreover, the stria-
tum is the second closest site to the lateral ventricle where dox-
ycycline is infused. Furthermore, the activation of neural stem/
progenitor cells in the subventricular zone through the intraven-
tricular administration of growth factors including brain-derived 
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neurotrophic factor can also turn the striatum into a regenera-
tive environment.7,8,32 Thus, we next evaluated neurogenesis and 
gliogenesis in the right striatum to determine whether the in vivo 
pluripotency factor expression can similarly turn the damaged 
striatum into a restorative environment.
The numbers of BrdU+ cells in both the DOX-H and DOX-L 
groups were 4.3- and 3.7-fold, respectively, significantly higher than 
in the PBS control group (Figure 3a; P < 0.001), suggesting that 
doxycycline-induced pluripotency factor expression increases the 
number of proliferating cells in the striatum. As in the subventricu-
lar zone, the number of BrdU+GFAP+ cells in the DOX-H group 
was 2.2-fold significantly higher than in the PBS control group, in 
which BrdU+GFAP+ cells were barely observed (Figure 3b,e–g; P 
< 0.001), suggesting that pluripotency factor expression robustly 
increases the number of newly generated astrocytes in the striatum. 
The numbers of BrdU+βIII-tubulin+ cells in the striatum were much 
lower than in the subventricular zone and were similar among all 
groups (Figure 3c,h–j), suggesting that neurogenesis in the stria-
tum is not altered by the expression of pluripotency factors. In addi-
tion, the levels of the glial scar marker CS-56 did not differ among 
the groups (Figure 3d,k–p), suggesting that the astrocytes that were 
newly generated by in vivo pluripotency factor expression do not 
increase the detrimental glial scar formation that inhibits neurore-
generation after ischemic brain damage.
We next determined whether the density of the astrocytes 
generated through proliferation varies in regions within the stria-
tum. The striatum was divided into five regions (Figure 4a) and 
the densities of BrdU+ and BrdU+GFAP+ cells in each region were 
evaluated. In the PBS group, the densities of BrdU+ cells were com-
parable between regions and the density of BrdU+GFAP+ cells was 
Figure 1  Study design and doxycycline injection. (a) Study design. Transient cerebral ischemia was induced by 20-minute bilateral carotid artery occlu-
sion (two vessel occlusion) in the doxycycline (DOX)-inducible reprogrammable mice. Thereafter, DOX or phosphate buffered saline (PBS, control buffer) 
was continuously infused into the right lateral ventricle via an osmotic pump over 7 days and BrdU was daily injected for 12 days. Behavioral tests such 
as the rotarod and ladder walking tests were performed. Four weeks after the cerebral ischemia induction, the mice were sacrificed and histologically 
analyzed. (b) DOX injection into the lateral ventricle via an osmotic pump (left side) to infuse low (12 ng/day, DOX-L) or high (1,200 ng/day, DOX-H). 
Brain damage is shown using TTC strain at 1 day after ischemic injury (right side). (c–e) Absence of dysplasia or tumor development in brain tissue. Four 
weeks after the initiation of DOX-H, DOX-L, or PBS infusion, brain sections were stained with hematoxylin and eosin and observed using a microscope. 
Neither dysplasia nor tumors were observed in any groups. Scale bars = 200 μm. BrdU, 5-bromo-2-deoxyuridine; TTC, 2,3,5-triphenyltetrazolium chloride.
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below the detection range in all regions (Supplementary Figure 
S2a,b and Figure 4b,c). In both DOX-L and DOX-H groups, the 
densities of BrdU+ and BrdU+GFAP+ cells showed a tendency 
to be high as the analyzed region is closer to the lateral ventricle 
where doxycycline was infused. This regional tendency showed 
that the density of BrdU+ cells was significantly higher in region 1, 
where is closest to the lateral ventricle, in the DOX-H and DOX-L 
groups (Supplementary Figure S2a). Furthermore, the density of 
BrdU+GFAP+ cells in region 1 in the DOX-H group was significantly 
higher than in regions 4 and 5 (P < 0.05) (Supplementary Figure 
S2b). Likewise, in regions 1, 2, and 3, the densities of BrdU+ cells in 
the DOX-H and DOX-L groups were significantly higher than PBS 
group (Figure 4b). The densities of BrdU+GFAP+ cells in region 1 
in the DOX-H and DOX-L groups were significantly higher than 
PBS group (P < 0.01 and P < 0.05, respectively) (Figure 4c). Taken 
together, these data indicate that the densities of all proliferated cells 
and proliferated astrocytes were significantly higher in the striatum 
regions closer to the lateral ventricle.
In vivo pluripotency factor expression enhances 
neovascularization
Neovascularization is a critical process for the recovery of isch-
emic tissue. We evaluated blood vessel density in the striatum by 
staining the tissue with an anti-CD31 antibody, which recognizes 
Figure 2 Increased number of newly generated neural progenitors and astrocytes induced by pluripotency factor expression in the 
 subventricular zone. After the induction of cerebral ischemia, the doxycycline (DOX)-inducible reprogrammable mice were infused with two dose of 
doxycycline (12 ng/day, DOX-L; 1,200 ng/day, DOX-H) or phosphate buffered saline (PBS, control buffer) into the right lateral ventricle for 7 days. To 
identify newly generated cells, the mice were daily injected daily with 5-bromo-2-deoxyuridine (BrdU) for 12 days. Four weeks after ischemia induc-
tion, histologic evaluations were performed. (a) The density of BrdU+ cells in the subventricular zone was significantly higher in both the DOX-H and 
DOX-L groups than in the PBS controls. n = 5/group; *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way analysis of variance (ANOVA) followed by a 
post-hoc Bonferroni comparison). (b–d) The density of newly generated neural progenitors, astrocytes, and neurons was determined through confocal 
microscopy by calculating the density of cells triple positive for 4ʹ,6-diamidino-2-phenylindole (DAPI) (blue, nuclei), BrdU (green), and cell type–specific 
markers such as Nestin, GFAP, and βIII-tubulin, respectively. The densities of BrdU+Nestin+ (b) and BrdU+GFAP+ cells (c) but not BrdU+βIII-tubulin+ cells 
(d) in both the DOX-H and DOX-L groups were significantly higher than in the PBS controls. n = 5/group; *P < 0.05, **P < 0.01, and ***P < 0.001 (one-
way ANOVA followed by a post-hoc Bonferroni comparison). (e–m) Representative confocal microscopic images. (g,j) Cells triple positive for DAPI, 
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a representative endothelial cell marker (Figure 5a,c). The num-
ber of CD31+ capillaries in the DOX-H group was 1.2- and 1.1-fold 
 significantly higher than in the PBS control and DOX-L groups 
(Figure 5d; P < 0.001 and P < 0.05, respectively), indicating that 
the neovascularization level is the highest in the DOX-H group. 
We next attempted to identify the potential underlying mechanism 
of the increased neovascularization in the ischemic brain. Given 
that astrocytes play crucial roles in brain neovascularization,33,34 
Figure 3 Pluripotency factor expression increases the number of newly generated astrocytes in the striatum. (a) The densities of BrdU+ cells in the 
striatum of both DOX-H and DOX-L groups were significantly higher than in the PBS controls. n = 5/group; **P < 0.01; ***P < 0.001 (one-way analysis 
of variance (ANOVA) followed by a post-hoc Bonferroni comparison). (b,c) The density of newly generated astrocytes and neurons was determined 
through confocal microscopy by calculating the density of cells triple positive for 4ʹ,6-diamidino-2-phenylindole (DAPI) (blue, nuclei), BrdU (green), and 
cell type–specific markers such as GFAP and βIII-tubulin, respectively. The density of BrdU+GFAP+ cells (b), but not BrdU+βIII-tubulin+ cells (c), was signifi-
cantly higher in the DOX-H group than in the DOX-L and PBS groups. n = 5/group; ***P < 0.001 (one-way ANOVA followed by a post-hoc Bonferroni 
comparison). (d) The density of area positive for CS-56, a marker of glial scar. The area of CS-56 staining did not differ among the groups (n = 5/group). 
(e–j) Representative confocal microscopic images of BrdU+GFAP+ cells (e–g) and BrdU+βIII-tubulin+ cells (h–j) in the striatum. (g) Three-dimensional 
images of cells triple positive for DAPI, BrdU, and GFAP are indicated with arrow heads in the right panel. Scale bars = 25 μm. (k–p) Representative fluo-
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the increased neovascularization induced by pluripotency factor 
expression might be, at least in part, attributable to the enhanced 
proliferative generation of astrocytes. As supportive data for 
this point, Western blotting showed that astrocytes expressed 
1.5-, 2.2-, and 1.6-fold higher levels of VEGFA, ANGPT1, and 
FGF2, respectively, than neuroblasts in vitro (Supplementary 
Figure S3a–c; P < 0.05). Furthermore, using confocal microscopy, 
we also observed that CD31+ blood vessels were frequently sur-
rounded by astrocytes (Figure 5e–m).
In vivo pluripotency factor expression enhances 
neuronal survival and synaptic plasticity
Astrocytes play a crucial role in neuroprotection by releasing 
several growth factors and cytokines.35,36 To test whether newly 
generated astrocytes and neovascularization induced by in vivo 
pluripotency factor expression can increase neuronal survival and 
synaptic plasticity, we evaluated the expression of the mature neu-
ronal marker NeuN and synaptic markers such as synaptophysin 
and PSD95 using qRT-PCR. We found that expression of striatal 
NeuN significantly increased in mice treated with DOX-H com-
pared to the PBS control group (Figure 6a; P < 0.05). Similarly, 
expression of synaptophysin and PSD 95 in the striatum signifi-
cantly increased in the DOX-H group compared to the DOX-L 
and PBS groups (Figure 6b,c; P < 0.01 and P < 0.001). We also con-
firmed that the number of NeuN+ cells (/mm3) and the fraction of 
area in the striatum that was NeuN+ (%) were significantly higher 
in mice treated with DOX-H (Figure 6d–h).
In situ pluripotency factor expression facilitates 
behavioral functional restoration after ischemic brain 
injury
To determine whether this in situ pluripotency factor expres-
sion enhances functional recovery in the ischemic brain damage 
model, we evaluated neurobehavioral functions using rotarod 
tests and ladder walking tests 2 and 4 weeks after the doxycycline 
infusion. Rotarod tests with constant (32 rpm) speed showed 
that the latency periods before falling in the DOX-H group were 
262.4 ± 18.8 and 241.1 ± 23.7 seconds at post-treatment 2  and 
4 weeks, respectively, which are 4.0- and 5.1-fold, significantly 
higher than those in the PBS control group (64.9 ± 26.9 and 
46.6 ± 15.1  seconds, respectively) (Figure 7a and Supplementary 
Video S1; P < 0.001). Rotarod tests with accelerating speed 
(4–80 rpm) also revealed that the latency periods before falling 
in the DOX-H group were 150.4 ± 5.0 and 140.7 ± 7.9 seconds 
at post-treatment 2 and 4 weeks, 1.5- and 1.8-fold significantly 
higher than those in the PBS control group (100.4 ± 14.7 and 
80.1 ± 15.4 seconds, respectively) (Figure 7b; P < 0.05 and 
P < 0.01), corroborating that pluripotency factor expression 
enhances the improvement of motor function. Ladder walk-
ing tests, which evaluate fine motor coordination, showed that 
Figure 4 Regional density of BrdU+ and BrdU+GFAP+ cells in the striatum. (a) The striatum was divided into five regions and each region was subjected to 
analysis. (b,c) Regional analysis. The density of BrdU+ and BrdU+GFAP+ cells in the right striatum from mice in the DOX group showed a tendency to decrease 
as the distance between the lateral ventricle and analyzed regions increased. The density of BrdU+ cells was comparable between the regions in the PBS group. 
(b) The densities of BrdU+ cells in regions 1, 2, and 3 of the DOX-H and DOX-L groups were significantly higher than in the PBS group (n = 5/group; *P < 0.05, 
**P < 0.01, and ***P < 0.001, one-way analysis of variance followed by a post-hoc Bonferroni comparison). (c) The density of BrdU+GFAP+ cells in region 1 in the 
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the forelimb slip rates among total steps in the DOX-H group 
at post-treatment 2 and 4 weeks were 3.3 ± 0.6% and 2.5 ± 0.4%, 
respectively, which are 2.0- and 3.0-fold, significantly lower than 
those in the PBS group (6.7 ± 1.5% and 7.5 ± 1.3%, respectively; 
Figure 7c; P < 0.05 and P < 0.01, respectively). The forelimb slip 
rate in the DOX-L group was 4.3 ± 0.8%, which is also 1.8-fold, 
significantly lower than that in the PBS group at post-treatment 
4 weeks (Figure 7c; P < 0.05), indicating that in situ pluripotency 
factor expression can enhance the recovery of coordinated motor 
function in this cerebral ischemia model.
To provide insight into the effects of pluripotency factor 
expression in mice in the absence of brain ischemia, we performed 
that sham-operated reprogrammable mice (such that occlusion 
of the carotid arteries did not occur) and then treated with PBS, 
DOX-L, or DOX-H via an osmotic pump. Up to 4 weeks after sur-
gery, there were no differences in rotarod performances among 
three groups (Supplementary Figure S4a,b). This result sug-
gests that in vivo pluripotency factor expression has no beneficial 
effect on sham-operated reprogrammable mice in the absence of 
brain ischemia and indicates that the protective effects of pluripo-
tency factors are ischemia-dependent. We also treated C57BL/6J 
wild-type mice with bilateral common carotid artery occlusion 
with PBS, DOX-L, or DOX-H. Although doxycycline has been 
shown to have a neuroprotective effect in a previously published 
Figure 5 Enhanced neovascularization by pluripotency factor expression in the striatum. Four weeks after ischemia induction, the blood vessel 
density was determined by immunofluorescent staining against CD31. (a–c) Representative fluorescent microscopic images. Scale bar = 100 μm. 
(d) The density of CD31+ capillaries in the striatum was significantly higher in DOX-H group than in both the DOX-L and PBS controls (n = 6/group; 
***P < 0.001 and *P < 0.05 respectively, one-way analysis of variance followed by a post-hoc Bonferroni comparison). (e–m) Confocal microscopic 
pictures showing blood vessels close to astrocytes. CD31+ endothelial cells lining blood vessels are surrounded with GFAP+ astrocytes in PBS (e–i), 
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paper,37 the rotarod performances of these mice were not differ-
ent among the groups up to 4 weeks after surgery in this study 
(Supplementary Figure S4c,d).
DISCUSSION
Our study is the first to report that in situ expression of pluripo-
tency factors facilitates functional recovery from injury in vivo. 
Although in vivo expression of pluripotency factors has been stud-
ied with respect to tumor development28 and reprogramming into 
pluripotency,29 it had not yet been investigated whether these fac-
tors can augment functional restoration of injured tissues.
This pluripotency factor–induced functional recovery was 
associated with proliferative generation of Nestin+ or GFAP+ cells 
in the subventricular zone and striatum. Given that the early 
responses to pluripotency factor expression include cell prolif-
eration,38 the source of these cells could be endogenous Nestin+ 
cells (neural progenitors) and GFAP+ cells (astrocytes), respec-
tively. However, it cannot be ruled out that these cells could be 
also derived from other cell types because transient overexpres-
sion of pluripotency factors can epigenetically activate the cells 
into an intermediate plastic state that allows cells to take on alter-
nate fates.11–13,39,40 Elucidating the source of these newly generated 
neural progenitors and astrocytes would require complex lineage 
tracing experiments,41,42 which are beyond the scope of the cur-
rent study. Because functional improvement was associated with 
selective expansion of neural progenitors and astrocytes, it might 
be speculated that these cell types are required for recovery from 
brain injury and the prevention of additional tissue damage. This 
idea is in line with previous results showing that neural stem/
progenitor cells, but not mature neurons, can lead to functional 
recovery when transplanted into damaged brain tissue43,44 and that 
astrocytes are responsible for the prevention of tissue damage and 
neuronal loss in several mouse models of brain injury.45 Our data 
are also compatible with results from a previous interesting report 
showing that gliogenic, but not neurogenic, neural stem/progeni-
tor cells promoted axonal growth, remyelination, angiogenesis, 
Figure 6 In vivo pluripotency factor expression enhances neural survival and synaptic plasticity. Gene expression of markers of neural survival 
and synaptic plasticity was evaluated by quantitative real-time polymerase chain reaction. (a) Expression of striatal NeuN significantly increased in 
mice treated with DOX-H compared to the phosphate buffered saline (PBS) control group (n = 4/group; *P < 0.05). (b,c) Similarly, expression of 
synaptic markers such as synaptophysin and PSD 95 significantly increased in the striatum in the DOX-H group compared to the DOX-L and PBS 
groups (n = 4/group; **P < 0.01, ***P < 0.001). (d,e) The number of NeuN+ cells (/mm3) and the fraction of area that was NeuN+ in the striatum (%) 
were significantly higher in mice treated with DOX-H (n = 5/group; *P < 0.05, ***P < 0.001). (f–h) Representative microscopic images of NeuN+ cells 

















































































































Molecular Therapy vol. 24 no. 9 sep. 2016 1545
Official journal of the American Society of Gene & Cell Therapy
Pluripotency Factors Promote Recovery From Injury
and locomotor functional recovery when transplanted into a 
mouse model of spinal cord injury.46
Here in the acute brain ischemia model, pluripotency factor–
induced astrogliosis was associated with functional restoration 
and neovascularization, which is compatible with previous studies 
showing that astrogliosis has beneficial effects in the acute phase 
of injury.45,47 However, the long-term consequence of astrogliosis 
could be detrimental45,47: It can produce glial scar and prevent 
neurogenesis from the endogenous progenitors or transplanted 
stem/progenitor cells and axonal regeneration. In this study, glio-
genesis induced by in vivo pluripotency factor expression did not 
increase the detrimental glial scar formation in the striatum of 
the damaged brain. Thus, the GFAP+ cells generated by pluripo-
tency factor expression might be a novel cell source with stem cell 
potential in the injured brain.47
Angiogenesis is essential for recovery from ischemic injury. 
The role of astrocytes in angiogenesis in the retina, a part of the 
central nervous system like the brain, has been relatively well char-
acterized48,49; here, astrocytes form a template that guides retinal 
angiogenesis in both normal development and injury-associated 
regeneration. Although the role of astrocytes in brain angiogen-
esis has yet to be elucidated, astrocytes have been proposed to 
be the cell type that forms the trophic microenvironment that 
supports angiogenesis and enables the survival of transplanted 
striatal tissue in the human brain.50 In this study, key angiogenic 
factors robustly expressed in astrocytes might contribute to this 
trophic environment that favors angiogenesis and tissue regenera-
tion. Furthermore, it is well established that astrocytes contribute 
to the formation of the blood–brain barrier, which is compatible 
with our results showing that CD31+ blood vessels are surrounded 
by GFAP+ cells. Previous studies showed that astrocytes, which 
produce the proangiogenic and neurogenic factors such as FGF2 
and VEGFA, can facilitate angiogenesis and neurogenesis and 
enhance functional recovery after cerebral ischemia and hypoxic-
ischemic brain injury.51–53 Taken together, these results suggest 
that the pluripotency factor–induced functional recovery would 
be mediated by the proliferative generation of astrocytes, which 
express factors that are both angiogenic and neurogenic.
Astrocytes are the main neural-lineage cell type for the 
maintenance of brain homeostasis and contribute to the neuro-
protection and survival of neuron as secretion of neurotransmit-
ters, cytokines, and growth factors.35,36 This study showed that 
in vivo expression of pluripotency factors induced an increase 
in the number of newly generated astrocytes without effects 
Figure 7. In situ pluripotency factor expression enhances recovery of neurobehavioral functions in mice with cerebral ischemia. Neurobehavioral 
functions were evaluated by rotarod tests at constant (a) and accelerating (b) speed and by ladder walking tests (c). Neurobehavioral functions in the 
DOX-H group were significantly better than in the phosphate buffered saline (PBS) controls at 2 and 4 weeks after the ischemic injury (n = 7/group; 
*P < 0.05, **P < 0.01, and ***P < 0.001 versus PBS, #P < 0.05, ##P < 0.01 versus DOX-L, one-way analysis of variance followed by a post-hoc Bonferroni 
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on neurogenesis, further suggesting motor function recovery. 
Expression of NeuN (a mature neuronal marker), synaptophy-
sin (a presynaptic marker), and PSD95 (a postsynaptic marker) 
also increased in a doxycycline-dependent manner, suggesting 
increased neuronal survival and synaptic plasticity. These results 
might provide an explanation for the relation between newly gen-
erated astrocytes induced by in vivo pluripotency factor expres-
sion and functional recovery. Additional experiments revealed 
that sham-operated reprogrammable mice, lacking occlusion of 
the carotid artery, that received either PBS, DOX-L, or DOX-H 
showed no beneficial effect in the absence of brain ischemia in the 
rotarod test up to 4 weeks after surgery (Supplementary Figure 
S4a,b), suggesting that the protective effects of pluripotency fac-
tors are ischemia-dependent.
It has been recently reported that doxycycline-induced in vivo 
expression of pluripotency factors can lead to the development 
of dysplasia or tumors including teratoma.29 Similar dysplasia has 
been previously observed in mice in which Pou5f1 expression was 
induced by doxycycline in vivo.28 However, we did not observe any 
dysplasia or tumor development in our study. This discrepancy 
may be attributable to differences in both delivery methods and 
analyzed tissues between our study and the others. In each of the 
other studies, doxycycline was systemically applied to the mice 
through drinking water,28,29 whereas doxycycline was given to the 
lateral ventricle in our study, where systemic effects of doxycycline 
would be minimal or negligible. Among the three studies, one 
study,29 but not the other two, showed the expression of pluripo-
tency factors in brain tissue. However, dysplasia or tumor devel-
opment in the brain was not described even in this study. In all 
three studies, this dysplasia or tumor development was observed 
predominantly in epithelial tissues from the stomach, intestine, 
pancreas, kidney, and skin, but not brain.
Many established studies have shown that gender-specific 
hormones such as estrogen and progesterone have neuroprotec-
tive effects on the ischemic brain.54,55 In this respect, this study 
is limited in that we have not performed experiments according 
to gender. Therefore, gender-specific responses to in vivo pluri-
potency factor expression in a model of brain ischemia should be 
examined in the future.
In conclusion, here we showed that in situ transient expression 
of the four pluripotency factors promoted functional recovery in 
a mouse model of cerebral ischemia. This facilitated functional 
recovery was associated with enhanced neovascularization and 
proliferative generation of astrocytes and/or neural progenitors. 
Our in situ pluripotency factor–mediated functional restoration 
provides insight into the recovery from tissue damage and poten-
tially enables the development of novel therapeutic modalities for 
restoration from tissue injury including cerebral ischemia.
MATERIALS AND METHODS
Mice.  The reprogrammable mice (Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-
Pou5f1,-Sox2,-Klf4,-Myc)Jae/J), in which the four pluripotency factors Pou5f1, Sox2, 
Klf4, and Myc are expressed in the presence of doxycycline,26 were pur-
chased from the Jackson laboratory (Bar Harbor, ME). Control C57BL/6J 
mice were also purchased from the Jackson laboratory. Mice were housed 
under climate controlled conditions with a 12-hour light/dark cycle and 
provided standard food and water ad libitum. Mice of both sexes, aged 
8–16 weeks, were used. All procedures were reviewed and approved by 
the Animal Care and Use Committee of the Yonsei University College of 
Medicine (2013–0220).
Experimental grouping.  A total of 62 reprogrammable mice were used in 
this study. For behavioral assessment, 21 mice were randomly assigned to 
either PBS, DOX-L, or DOX-H (n = 7 each). Of this group, 15 mice were 
used for histological assessment at 4 weeks post-treatment (n = 5 each). 
An additional 12 mice were used for qRT-PCR experiments to evaluate 
the expression of the mature neuronal marker NeuN and synaptic markers 
such as synaptophysin and PSD95 at 4 weeks post-treatment (n = 4 each). 
To evaluate the expression of in vivo pluripotency factors, 12 mice were 
also sacrificed 3 days after the infusion of doxycycline via an osmotic pump 
(n = 4 each). An additional 17 reprogrammable mice that received sham 
operations were used to provide insight into the effects of pluripotency fac-
tor expression in the absence of brain ischemia. (n = 5, PBS; n = 6, DOX-L; 
n = 6, DOX-H). A total of 14 C57BL6/J wild-type mice were also used for 
behavioral assessment to examine whether doxycycline has a neuroprotec-
tive effect (n = 5, PBS; n = 4, DOX-L; n = 5, DOX-H).
Ischemic brain injury induction and doxycycline infusion. Mice were 
anesthetized via i.p. injection of ketamine (100 mg/kg) and xylazine 
(10 mg/kg). Transient cerebral ischemia was induced by bilateral com-
mon carotid artery occlusion for 20 minutes as previously described,27,56 
after which mice were continuously injected with low (1 μg/ml; DOX-L) 
or high (100 μg/ml; DOX-H) concentrations of doxycycline (No. 631311; 
Clontech, Mountain View, CA) in PBS, or PBS (solvent control) into the 
lateral ventricle via a micro-osmotic pump (100 μl volume; Alzet 1007D, 
Cupertino, CA) at a speed of 0.5 μl/hour (12 ng or 1,200 ng doxycycline/
day). The infusion cannula (Brain Infusion Kit 3; Durect, Cupertino, CA) 
was inserted using stereotaxic coordinates (AP +0.3 mm from Bregma; ML 
−0.7 mm from Bregma; DV −2.0 mm from Dura) into the lateral ventricle 
(Figure 1b), and the connected osmotic pump was placed in the dor-
sal subcutaneous tissue. Mice were daily given an i.p. injection of BrdU 
(50 mg/kg, Sigma-Aldrich, St. Louis, MO) for 12 days, beginning after ste-
reotaxic surgery. Histologic evaluation was performed 4 weeks after the 
surgery (Figure 1a). For the sham-operated control group, reprogramma-
ble mice were first deeply anesthetized and then received the same surgical 
procedure as above without actual occlusion of carotid arteries. The mice 
were randomly treated with either low (1 μg/ml; DOX-L) or high (100 
μg/ml; DOX-H) concentrations of doxycycline or PBS (solvent control), 
which were infused into the lateral ventricle via a micro-osmotic pump.
Neurobehavioral assessment.  Neurobehavioral function was evaluated at 
1, 14, and 28 days after the surgery. The rotarod (No. 47600; UGO Basile, 
Comerio, VA, Italy) test was used to assess motor coordination and balance 
using constant speed (32 rpm) and accelerating speed (4–80 rpm) para-
digms. For this assessment, mice were placed on a rotarod treadmill, and 
the latency to fall, which is the length of time that the animals remained 
on the rolling rod, was measured. The latency period before mice fell from 
the rod was measured twice during each test, and individual tests were 
terminated at a maximum latency of 300 seconds.7,52 For the ladder walk-
ing test, the mice were required to walk a distance of 1 m three times on 
a horizontal ladder with unevenly spaced metal rungs (Jeung Do B&P, 
Seoul, South Korea). The number of slips from the transverse rungs with 
each forelimb was measured by videotape analysis. The percentage of slips 
on the transverse rungs of the ladder relative to the total number of steps 
taken was calculated.7,52
Cell culture.  Mouse embryonic fibroblasts were isolated from the repro-
grammable mice as previously described.26 Mouse embryonic fibroblasts 
seeded at a density of 1 × 104 cells/well in six-well plates were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (FBS; Gibco Invitrogen) 
and 1% antibiotics (penicillin streptomycin; Gibco Invitrogen). Mouse 
embryonic fibroblasts were daily treated with various doses of doxycycline 
(10, 100, 500, 1,000 ng/ml) for 7 days and subjected to RT-PCR.
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The mouse astrocyte cell line (C8-D1A; Astrocyte Type 1 clone, 
ATCC, CRL-2541) and neuroblast cell line (N1E-115, ATCC, CRL-
2263) were cultured in DMEM and DMEM without sodium pyruvate 
(No. 11965-092; Gibco Invitrogen), respectively, both supplemented 
with 10% FBS and 1% antibiotics (penicillin, streptomycin). Each cell 
line was seeded at a density of 8 × 105 cells/100-mm culture dish; 1 day 
after seeding, the cells were washed six times using DMEM without FBS. 
This washing procedure efficiently eliminated all serum proteins, because 
we did not detect any trace of bovine albumin, the major serum protein. 
The cells were incubated in this FBS-free media for 48 hours and then 
subjected to Western blotting.
Immunohistochemistry.  Immunohistochemistry was performed as pre-
viously described.7 Briefly, the animals were sacrificed and perfused with 
4% paraformaldehyde. The harvested brain tissues were cryosectioned 
at 16-μm thickness along the coronal plane and immunohistochemistry 
staining was performed on four sections over a range of >128 µm (AP + 
1.0 mm to AP − 0.2 mm from Bregma). Sections were stained with pri-
mary antibodies against BrdU (1:200; Abcam, Cambridge, UK), βIII-
tubulin (1:400; Covance, Princeton, NJ), GFAP (1:400; Abcam), Nestin 
(1:400; Abcam), NeuN (1:200; Abcam), CS-56 (1:200; Abcam), and CD31 
(1:200; BD Bioscience, San Jose, CA) and secondary antibodies such as 
Alexa Fluor 488 goat anti-Rat (1:400; Invitrogen), Alexa Fluor 568 goat 
anti-Rabbit (1:400; Invitrogen), and Alexa Fluor 594 goat anti-Mouse 
(1:400; Invitrogen) and mounted on glass slides with fluorescent mount-
ing medium containing 4ʹ,6-diamidino-2-phenylindole (Vectorshield, 
Vector, Burlingame, CA). The stained sections were analyzed using confo-
cal microscopy (LSM700; Zeiss, Gottingen, Germany) and the MetaMorph 
Imaging System (Molecular Device, Sunnyvale, CA). The densities of 
blood vessels and mature neurons were evaluated using a fluorescent 
microscope (BS51; Olympus, Tokyo, Japan) and the MetaMorph Imaging 
System. Images of glial scarring were taken using a fluorescent microscopy 
(Axio Imager M2; Zeiss) and the density was evaluated using ZEN Imaging 
Software (Blue edition; Zeiss).
2,3,5-triphenyltetrazolium chloride staining.  Infarct region were con-
firmed by 2,3,5-triphenyltetrazolium chloride (Sigma) staining. At 1 day 
after bilateral common carotid artery occlusion, brains were sectioned into 
2.0 mm coronal sections using a mouse brain matrix. The sections were 
incubated in 2% 2,3,5-triphenyltetrazolium chloride at 37 °C for 20 min-
utes. The brain sections were washed in PBS and then stored in 4% para-
formaldehyde at 4 °C refrigerator. The sections were photographed with 
digital camera (Figure 1b).
RT-PCR.  RNA was isolated from the mouse embryonic fibroblasts using 
Trizol (Invitrogen Life Technologies). cDNAs, which was synthesized from 
1 μg total RNA using the cDNA kit (Invitrogen Life Technologies), were 
subjected to PCR using a RT-PCR analysis kit (Bioneer, Daejeon, South 
Korea) according to the manufacturer’s instructions and a Gene Amp 
PCR system 9700 (Applied Biosystems/Life Technologies, Carlsbad, CA). 
The primer sequences are described in Supplementary Table S2. The 
thermocycler conditions were as follows: denaturation for 1 minute at 
95 °C, followed by 35 cycles of 95 °C for 30 seconds, 58 °C for 30 seconds, 
and 72 °C 30 seconds. PCR products were subjected to 1.5% agarose gel 
electrophoresis.
qRT-PCR.  One microgram of purified total RNA was used as a template 
to generate the cDNA using a ReverTra Ace qPCR TR master Mix with 
gDNA remover (TOYOBO). Then, 2 μl of cDNA in a total volume of 
20 μl was used in the following reaction. The qRT-PCR was performed 
in triplicate on a LightCycler 480 (Roche Applied Science, Mannheim, 
Germany) using the LightCycler 480 SYBR Green master mix (Roche 
Applied Science). The thermocycler conditions were as follows: amplifica-
tions were performed starting with a 300-second template preincubation 
step at 95 °C, followed by 40 cycles of 95 °C for 5 seconds, 60 °C for 20 
seconds, and 95 °C for 15 seconds. The melting curve analysis began at 
95 °C for 15 seconds, followed by 1 minute at 60 °C. The specificity of the 
amplification product was confirmed by an examination of the melting 
curve, which showed a distinct single sharp peak with the expected melt-
ing temperature (Tm) for all samples. A distinct single peak indicates that 
a single DNA sequence was amplified during qRT-PCR. Glyceraldehyde 
3-phosphate dehydrogenase was used as an internal control. The expres-
sion of each gene of interest was obtained using the 2−ΔΔCt method. The 
primer sequences are described in Supplementary Table S2.
Western blot analysis.  Harvested cells were lysed in 50 μl cold lysis buf-
fer (50 mmol/l Tris-HCl, pH 7.5, 1% Triton X-100, 150 mmol/l NaCl, 
0.1% sodium dodecyl sulfate, 1% sodium deoxycholate) with a protease 
inhibitor cocktail (Sigma-Aldrich). Cell lysates were then centrifuged at 
13,000g for 15 minutes at 4 °C. The supernatant was harvested, and the 
protein concentration was determined using a protein assay kit (Bio-
Rad Laboratories, Hercules, CA). Proteins (30 μg) dissolved in sample 
buffer (60 mmol/l Tris-HCl, pH 6.8, 14.4 mmol/l β-mercaptoethanol, 
25% glycerol, 2% sodium dodecyl sulfate, and 0.1% bromophenol blue) 
were denatured for 10 minutes at 70 °C and subjected to electrophore-
sis on a 10% sodium dodecyl sulfate polyacrylamide gel. Separated pro-
teins were transferred onto 0.45 mm invitrolon polyvinylidene difluoride 
(Invitrogen) membrane using an XCell IITM Blot Module (Invitrogen). 
The membranes were blocked for 1 hour in TBST (Tris-buffered saline (10 
mmol/l Tris-HCl, pH 7.5, 150 mmol/l NaCl) containing 0.05% Tween 20) 
supplemented with 5% nonfat dry milk (Bio-Rad Laboratories) at room 
temperature, washed three times with TBST, and incubated at 4 °C over-
night in TBST supplemented with 5% nonfat dry milk and the antibod-
ies against ANGPT1 (1:500; Abcam), VEGFA (1:1,000; Abcam), FGF2 
(1:500; Abcam), or glyceraldehyde 3-phosphate dehydrogenase (1:1,000; 
Cell Signaling Technology, Danvers, MA). The blots were washed three 
times with TBST and incubated for 1 hour with horseradish peroxidase– 
conjugated secondary antibodies (1:3,000; Santa Cruz Biotechnology, 
Dallas, TX) at room temperature. After washing three times with TBST, 
the protein was visualized with an enhanced chemiluminescence detection 
system (Amersham Pharmacia Biotech, Little Chalfont, UK).
Statistical analysis.  All data were expressed as means ± SEM. The vari-
ables between among groups were analyzed using one-way analysis of 
variance followed by a post-hoc Bonferroni comparison using the SPSS 
statistics (IBM, Armonk, NY; version 20.0). The comparison of variables 
between two groups was used using Student’s t-test. A P value <0.05 was 
considered statistically significant.
SUPPLEMENTARY MATERIAL
Figure S1. Doxycycline-induced expression of the pluripotency 
factors.
Figure S2. Regional density of BrdU+ and BrdU+GFAP+ cells in the 
striatum.
Figure S3. Expression of angiogenic factors by astrocytes.
Figure S4. Neurobehavioral evaluation in both sham-operated 
reprogrammable mice and C57BL6/J mice with bilateral common 
carotid artery occlusion.
Table S1. Cell type analysis of BrdU+ cells in the subventricular zone 
and the striatum
Table S2. The sequences of primers used for RT-PCR and qRT-PCR.
Video S1. In situ pluripotency factor expression improves rotarod 
performance in mice with cerebral ischemia.
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